Abstract:Aim: The aim of the study was to investigate whether miR-126, a regulator of MAPK signaling via targeting sprouty-related EVH1 domain-containing protein 1 (SPRED1) mRNA, is involved in the process by which icariside II (ICA II) ameliorates endothelial dysfunction in human cavernous endothelial cells (hCECs) exposed to a diabetic-like environment. Materials and methods: Primary hCECs were isolated and divided into three groups, normal control, diabetes mellitus (DM), and DM treated with ICA II. The cell proliferation and migration abilities of the hCECs were examined. The expression levels of endothelial-related microRNAs and relative target mRNAs (SPRED1, phosphoinositol-3 kinase regulatory subunit 2, and vascular cell adhesion molecule 1) of miR-126 were determined by real-time PCR. The protein expression of endothelial nitric oxide synthase, receptor for advanced glycation end products, and SPRED1, and MAPK signaling activities was determined by Western blot analysis. In addition, miR-126 agomir and antagomir were used for transfection into hCECs to further testify the association between miR-126 and its targeting mRNA SPRED1. Results: hCECs induced with glucose plus advanced glycation end product-BSA showed a significant decrease in endothelial nitric oxide synthase, Ki-67, and miR-126 expression; a downregulated cell migration ability and an increased receptor for advanced glycation end products level. ICA II could partially reverse these changes. SPRED1 mRNA showed a contrary tendency with the miR-126-3p changes. The level of SPRED1 protein increased after the hCECs were induced with glucose plus advanced glycation end product-BSA, and ICA II could rescue its aberrant expression. In addition, the MAPK pathway was downregulated in the hCECs under diabetic conditions, and ICA II could partially enhance its signaling activities. miR-126 was obviously downregulated, and SPRED1 was accordingly upregulated after miR-126 antagomir transfection, while ICA II treatment could recover the expressions of both miR-126 and SPRED1. Moreover, the upregulation of miR-126 and the inhibition of SPRED1 were noticed in the diabetic hCECs by further transfection with miR-126 agomir. Conclusion: ICA II could ameliorate endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in hCECs exposed to a diabetic-like environment, and ICA II might be a protective agent for endothelial function in diabetic ED.

AB239. Icariside II enhances endothelial nitric oxide synthase expression by suppressing miR-155 in diabetic-like human cavernous endothelial cells

AB184. Icariside II Induces NO Production in Human Cavernous Endothelial Cells Via the Activation of Enos by Mir-155

AB037. Icariside II improves human cavernous endothelial cells function by regulating miR-155/eNOS signal pathway

AB238. Effect of Icariside II on miR-126 pathway on human cavernous endothelial cells exposed to a diabetic-like environment

IcarisideⅡ improves human cavernous endothelial cells function by regulating miR-155/eNOS signal pathway

Icariside II ameliorates endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in diabetic human cavernous endothelial cells.

Effect of icarisideⅡ on miR-181c and its targeting genes KLF6, KLF9, KLF10 and KLF15 in a ;diabetic-like human cavernous endothelial cells

Icariside Ii Prevents High-Glucose-Induced Injury On Human Cavernous Endothelial Cells Through Akt-Enos Signaling Pathway

AB178. Molecular Biology for Genitourinary System Diseases and Sexual Dysfunction Icariside II Prevents High-Glucose-induced Injury on Human Cavernous Endothelial Cells Through Akt-eNOS Signaling Pathway

Effects of Icariside II on Improving Erectile Function in Rats with Streptozotocin-Induced Diabetes.

AB176. Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats

Effect of Icarisid II on Diabetic Rats with Erectile Dysfunction and Its Potential Mechanism Via Assessment of AGEs, Autophagy, Mtor and the NO-cGMP Pathway.

Icariin enhances neuronal survival after oxygen and glucose deprivation by increasing SIRT1.

Icarisid II, a PDE5 inhibitor from Epimedium wanshanense, increases cellular cGMP by enhancing NOS in diabetic ED rats corpus cavernosum tissue.

Icariside II induces rapid phosphorylation of endothelial nitric oxide synthase via multiple signaling pathways

MP89-05 EFFECT OF ICARISIDE II ON MIR-126 PATHWAY ON HUMAN CAVERNOUS ENDOTHELIAL CELLS EXPOSED TO A DIABETIC-LIKE ENVIRONMENT

Icariside II attenuates cardiac remodeling via AMPKα2/mTORC1 in vivo and in vitro.

Icariin Ameliorates Streptozotocin-Induced Diabetic Retinopathy in Vitro and in Vivo

Effect of Icariside II and Metformin on Penile Erectile Function, Glucose Metabolism, Reaction Oxygen Species, Superoxide Dismutase, and Mitochondrial Autophagy in Type 2 Diabetic Rats with Erectile Dysfunction

Icariin Attenuates Vascular Endothelial Dysfunction by Inhibiting Inflammation Through GPER/Sirt1/HMGB1 Signaling Pathway in Type 1 Diabetic Rats

Effects Of Icariside Ii On Corpus Cavernosum And Major Pelvic Ganglion Neuropathy In Streptozotocin-Induced Diabetic Rats